The effect of correction of metabolic acidosis in chronic kidney disease on intrarenal RAS activity.

Completed

• Conditions: 10029149; chronic kidney disease; chronic renal disease

• Registration Number: NL-OMON45074
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 48

Inclusion Criteria

- male or female adult (>18 years)
- chronic kidney disease stage 4, i.e. eGFR (MDRD) 15-30 ml/min
- plasma bicarbonate concentration of <24 and >15 meq/L, the latter because in that case it seems highly recommended to start sodiumbicarbonate suppletion and not to postpone this

Exclusion Criteria

- plasma bicarbonate level >24 meq/L or <15 meq/L
- sodiumbicarbonate use in the 6 months preceeding the study
- a kidney transplant in situ
- heart failure
- liver cirrhosis
- blood pressure > 140/90 mmHg despite the use of 3 different antihypertensives
- a history of inadherence to medication
- use of calcineurin inhibitors (these immunosuppressive drugs are known to induce metabolic acidosis and influence electrolytes and acid-base balance)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>the main study parameter is the change in urinary renin values (as urinary<br /><br>renin is assumed to most closely represent intrarenal RAS activity).</p><br>